Weight-loss drug trial reports kids given ingredient in Wegovy no longer obese

ctvnews.ca 8 h Canada

Novo Nordisk said on Monday that in a late-stage trial, 40.4 per cent of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.

Aggregated from the leading newsrooms of the country. Every story links to its original source.